Radio and PodcastLive Radio & PodcastsOpening Radio and Podcast...
Radio and PodcastLive Radio & PodcastsFetching podcast shows and categories...
Radio and PodcastLive Radio & PodcastsFetching podcast episodes...
A summary of new trial data, guideline recommendations and expert opinion across diabetes care, run by Diabetes Knowledge into Practice (https://diabetes.knowledgeintopractice.com), featurin...
Join Prof. Francesco Giorgino and Dr. Darren McGuire as they discuss personalisation of treatment for patients with both type 2 diabetes and...
Join Prof. Francesco Giorgino and Dr. Shehla Shaikh as they discuss strategies to help support type 2 diabetes patients during cultural even...
Join Prof. Francesco Giorgino and Dr. Alice Cheng for a discussion on the importance of being culturally sensitive during shared decision-ma...
Join Prof. Francesco Giorgino and Dr. Erika Bezerra Parente as they identify some takeaways from EASD 2023, including data and discussions o...
In this epsisode Prof. Francisco Giorgino & Dr. Vanita Aroda explore how vital it is that we aim to control more than blood glucose levels w...
Join Prof. Francisco Giorgino & Dr. Richard E. Pratley as they discuss their highlights from the 83rd American Diabetes Association (ADA 202...
This year’s EASD was a hybrid event, with delegates able to join either in person in Stockholm, or online via the virtual platform. As usual...
The SURPASS program of phase 3 clinical trials led to the 2022 FDA approval and positive CHMP opinion of the first GIP/GLP-1 receptor agonis...
Heterogeneity across available glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes means that agents should be prescri...
The last two years have provided updated guidelines on management of chronic kidney disease in type 2 diabetes alongside new regulatory appr...
The past year has included the release of new guidelines on cardiovascular disease prevention and further data on cardioprotective agents in...
This year saw the regulatory approval of the first dual GIP/GLP-1 dual agonist for type 2 diabetes. With several other multi-agonists in dev...
The importance of weight loss in type 2 diabetes was a major topic at the recent American Diabetes Association (ADA) 2022 Scientific Session...
The ADA 2022 was full of interesting symposia, updates on ongoing clinical trials, and a draft of an updated ADA-EASD consensus report. This...
This is a special episode brought to you in association with Hepatology Knowledge into Practice. NASH has historically had very few treatmen...
GLP-1 receptor agonists including semaglutide have been shown to offer benefits for glycemic control, weight loss and cardiovascular protect...
In late 2020, we published an episode looking at the management of diabetes and heart failure when both present together. Since then, a weal...
The 2022 Standards of Medical Care in Diabetes is published every year by the American Diabetes Association to reflect the latest available...
This is a special episode brought to you in association with Hepatology Knowledge into Practice. NASH occurs in around 20% of individuals wi...
Description: A year ago, we published an episode looking at diabetes management in the context of ongoing restrictions in many parts of the...
This is a special episode brought to you in association with Hepatology Knowledge into Practice. People with type 2 diabetes or obesity are...
This is a special episode brought to you in association with Hepatology Knowledge into Practice. Non-alcoholic fatty liver disease (NAFLD) i...
An introduction to the podcast - who we are, and why we're doing this